Stock Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of some unusual options trading activity on Monday. Stock traders purchased 86,445 put options on the company. This represents an increase of approximately 136% compared to the average volume of 36,670 put options.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Oarsman Capital Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Wilmington Savings Fund Society FSB acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $50,000. Ameliora Wealth Management Ltd. acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at $66,000. Finally, IFP Advisors Inc boosted its position in Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $13.59 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company’s 50-day simple moving average is $15.64 and its 200 day simple moving average is $17.76. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $22.80. The stock has a market cap of $15.40 billion, a P/E ratio of -9.37, a PEG ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on TEVA shares. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Monday. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, January 30th. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Finally, Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.